Reviva Pharmaceuticals‘ RP5063 prevented rats from developing pulmonary arterial hypertension (PAH), according to a Canadian study. In addition to precluding heart and blood vessel damage in the animals, RP5063 decreased levels of cytokines, or proteins associated with inflammation. The study, published in the European Journal of Pharmacology, was titled “…
Bellerophon Therapeutics has updated clinical trials testing its investigative INOpulse system for several forms of pulmonary hypertension (PH). The update is part of the company’s second-quarter 2017 financial report. The INOvation-1 trial (NCT02725372) seeks to evaluate the safety, tolerability and effectiveness of pulsed, inhaled nitric oxide (iNO) compared to placebo…
Tracking long-term changes in measurements associated with pulmonary hypertension patients’ death from heart disease can help doctors do a better job of identifying those at higher risk of such deaths, a study reports. The hallmark of what doctors call pulmonary arterial hypertension due to congenital heart disease, or PAH-CHD, is…
Human cardiotrophin 1 protein (hCT1) stimulates heart muscle growth in rats with induced right heart failure (RHF) due to severe pulmonary arterial hypertension, leading to improved heart function, a new study shows. The results suggest that hCT1 could be beneficial for patients with an intractable form of heart failure. The study, “Cardiotrophin 1…
The Pulmonary Hypertension Association (PHA) has expanded its Pulmonary Hypertension Care Centers (PHCC) network by accrediting two new pulmonary hypertension (PH) programs as Centers for Comprehensive Care (CCC). The two new additions, the Pulmonary Hypertension Programs at Cincinnati Children’s Hospital Medical Center, in Cincinnati, Ohio, and…
Pulmonary hypertension expert Paresh Giri believes in patient support groups. The prevailing view is that the groups’ main function is helping patients cope with their condition. They certainly do that, but their gatherings are also places where valuable information is exchanged, Giri said. “For example, to hear how one person…
The ratio between the proteins MMP2 and TIMP4 in blood samples of idiopathic pulmonary arterial hypertension (iPAH) patients was found to predict disease worsening and mortality in a German study. It also correlated with mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance, and other indicators of disease progression. The study, “…
The U.S. Food and Drug Administration (FDA) agreed to the Phase 2 study of INOpulse in pulmonary hypertension (PH) patients with interstitial lung disease. This is the third potential treatment application of INOpulse, a device that delivers inhaled nitric oxide, developed by Bellerophon Therapeutics. In patients with pulmonary…
The Phase 4 multicenter, observational PaTTerN registry evaluating the use of Inomax (nitric oxide) in newborns with pulmonary hypertension (PH) has enrolled its first patient, Mallinckrodt Pharmaceuticals announced. The registry (NCT03132428) is actively recruiting participants, said the British drug conglomerate. Persistent PH in newborns is a serious, sometimes fatal, condition marked by increased pulmonary vascular pressure.
A new study shows that CMR (cardiovascular magnetic resonance) fluoroscopy-guided heart catheterization is a safe method with an appropriate procedure time, high rate of success, and better accuracy than the more commonly used techniques to determine hemodynamic parameters. The study, titled, “CMR fluoroscopy right heart catheterization for cardiac…
Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort of pediatric patients with pulmonary arterial hypertension (PAH) in Japan. The study, “Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial…
Complexa has obtained $62 million in financing to continue advancing its pulmonary arterial hypertension therapy CXA-10 through the clinical trial process. The company is also developing CXA-10 as a treatment for kidney disease focal segmental glomerulosclerosis, or FSGS. Companies that participated in Complexa’s third round of financing included New Enterprise…
Get regular updates to your inbox.
